Omeros (OMER) Gross Margin (2014 - 2026)

Omeros (OMER) posted Gross Margin of 94.07% for Q1 2026, down 31.42% sequentially from 137.17% in Q4 2021.

Omeros (OMER) Gross Margin (2014 - 2026) Analysis & Trends

Omeros has reported Gross Margin for 9 years, with the latest figure at 94.07% in Q1 2026.

Quarterly Gross Margin changed N/A year-over-year to 94.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 261.58% (down 34349.0% YoY) and the FY2020 annual result came in at 98.78%, down 45.0% from the prior year.
Gross Margin retreated to 94.07% in Q1 2026 per OMER's latest filing, from 137.17% in the prior quarter.
Over five years, Gross Margin peaked at 94.07% in Q1 2026 and troughed at 94.07% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	91.59%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	90.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	89.76%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	60,631,834.75%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	76.90%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	84.20%
10	Omeros	1.24 Bn	1.24 Bn	27.73 Mn	97.20%

Historic Data

Download Data

Date	Value
Jun 30, 2026	97.20%
Mar 31, 2026	94.07%
Dec 31, 2021	137.17%
Sep 30, 2021	98.89%
Jun 30, 2021	98.81%
Mar 31, 2021	98.75%
Dec 31, 2020	99.18%
Sep 30, 2020	98.46%
Jun 30, 2020	98.91%
Mar 31, 2020	98.87%
Dec 31, 2019	98.80%
Sep 30, 2019	99.07%
Jun 30, 2019	99.79%
Mar 31, 2019	99.40%
Dec 31, 2018	99.29%
Sep 30, 2018	99.22%
Jun 30, 2018	92.99%
Mar 31, 2018	87.22%
Dec 31, 2017	96.62%
Sep 30, 2017	99.15%